Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in Burundi has been experiencing a steady growth over the past few years.
Customer preferences: Customers in Burundi have been showing a growing preference for generic drugs as they are more affordable than branded drugs. This is due to the fact that the majority of the population in Burundi lives in poverty and cannot afford expensive drugs. Additionally, there is a high prevalence of infectious diseases in the country, which has increased the demand for pharmaceuticals.
Trends in the market: The Other Pharmaceuticals market in Burundi has been witnessing a trend towards the manufacturing of generic drugs. This is due to the increasing demand for affordable drugs and the lack of patent protection laws in the country. The government has been encouraging the production of generic drugs to make healthcare more accessible to the population. Additionally, there has been a trend towards the production of essential medicines, which are drugs that are considered to be necessary for the treatment of common diseases.
Local special circumstances: Burundi is a small landlocked country in East Africa with a population of approximately 11 million people. The country has a high prevalence of infectious diseases such as malaria, tuberculosis, and HIV/AIDS. The healthcare system in the country is underdeveloped and lacks the necessary infrastructure and resources to provide adequate healthcare to the population. This has led to a high demand for pharmaceuticals in the country.
Underlying macroeconomic factors: Burundi is one of the poorest countries in the world with a GDP per capita of less than $300. The country heavily relies on foreign aid and has a weak economy. The pharmaceutical industry is underdeveloped in the country due to the lack of investment and infrastructure. However, the government has been implementing policies to encourage the growth of the industry and make healthcare more accessible to the population. Additionally, the country is a member of the East African Community, which has been promoting regional integration and trade. This has created opportunities for the pharmaceutical industry to expand and reach new markets.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
